Under this agreement, Bristol-Myers Squibb and Gilead share responsibility for commercializing Atripla throughout the EU and certain other European countries. Gilead will record revenues from future net sales of Atripla in most of the European countries, while Bristol-Myers Squibb will record revenues in most of the European countries at percentages relative to the contribution represented by its individual product.
Bristol-Myers Squibb recently concluded an agreement with Merck & Co., under which Merck granted Bristol-Myers Squibb rights to co-commercialize Atripla with Gilead in all of the EU and certain other European countries.
If approved, Atripla would represent the first and only once-daily single tablet regimen for HIV-1 infection in the EU. The companies expect the European Commission to issue its decision by the end of the year.
Atripla is currently sold in the US and Canada through a joint venture between Bristol-Myers Squibb and Gilead. Atripla was approved by the FDA in July 2006 and by Health Canada in October 2007.